ADMA Biologics Inc (ADMA)

Return on assets (ROA)

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Net income (ttm)	US$ in thousands	68,132	34,788	-3,645	-28,240	-22,827	-40,292	-47,686	-65,905	-70,322	-73,135	-78,275	-71,647	-74,406	-73,610	-74,883	-75,748	-66,901	-61,422	-54,456	-48,279
Total assets	US$ in thousands	390,618	376,399	350,875	329,182	348,997	343,027	340,788	348,461	300,558	296,932	308,032	276,253	238,640	232,814	235,667	207,673	189,976	191,542	210,524	127,091
ROA		17.44%	9.24%	-1.04%	-8.58%	-6.54%	-11.75%	-13.99%	-18.91%	-23.40%	-24.63%	-25.41%	-25.94%	-31.18%	-31.62%	-31.77%	-36.47%	-35.22%	-32.07%	-25.87%	-37.99%

September 30, 2024 calculation

ROA = Net income (ttm) ÷ Total assets
= $68,132K ÷ $390,618K
= 17.44%

ADMA Biologics Inc's return on assets (ROA) has fluctuated significantly over the past several quarters. The ROA was positive in the most recent quarter at 17.44%, indicating that the company generated a strong return relative to its assets during that period. This marked improvement from the previous quarter's ROA of 9.24% suggests an upward trend in the company's asset efficiency.

However, the company experienced negative ROA values in the quarters leading up to the most recent period, with the lowest ROA recorded at -36.47% in the fourth quarter of 2020. These negative ROA values signify that the company's asset utilization and/or profitability were not optimal during those periods.

It is essential for ADMA Biologics Inc to sustain positive ROA values over the long-term to demonstrate effective management of its assets and generate profitable returns for its stakeholders. Further analysis of the company's operational efficiency, profitability, and asset management practices is recommended to understand the factors driving these fluctuations in ROA.